Europska Unija - hrvatski - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - Визудин indiciran za liječenje:odrasli s экссудативной (vlažna) senilne makularne degeneracije (amd) s pretežno klasične subfoveal хориоидальной неоваскуляризации (ХНВ); ili odrasli s subfoveal хориоидальной неоваскуляризации sekundarne patološkog kratkovidnosti.

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

kk biovit d.o.o., zagreb, hrvatska - sorbinska, mravlja, octena, mliječna i propionska kiselina, amonijev formijat, l-askorbinska kiselina, limunska kiselina, mono- i digliceridi masnih kiselina i prirodni ekstrakt kvasaca - koncentrirana otopina za primjenu u vodi za piće - peradi i svinja

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - Луцентис prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd)liječenje vida zbog хориоидальной неоваскуляризации (ХНВ)poremećaje vida zbog dijabetes pomagala макулярного edema (ДМО)poremećaje vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr).

Europska Unija - hrvatski - EMA (European Medicines Agency)

elanco gmbh - benazepril hidroklorid, pimobendan - ace inhibitori, kombinacije - psi - za liječenje kongestivnog zatajenja srca zbog предсердно-желудочковая zatajenje ventila ili дилатационной кардиомиопатии kod pasa.

Europska Unija - hrvatski - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europska Unija - hrvatski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europska Unija - hrvatski - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba

Europska Unija - hrvatski - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - Эйлеа indiciran za odrasle za liječenje:неоваскулярной (vlažna) senilne makularne degeneracije (amd), poremećaj vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr);vida zbog dijabetes pomagala макулярного edema (ДМО);vida zbog миопической хориоидальной неоваскуляризации (миопической ХНВ).